Orally Administrated Risedronate Can Commit V.GAMMA.2V.DELTA.2 T Cells to IFN-.GAMMA. Secreting Effectors in Patients With Osteoporosis

Biomedical Research - Japan
doi 10.2220/biomedres.25.1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Biomedical Research Press

Related search

.GAMMA..DELTA. T Lymphocytes and Their V.GAMMA.9 and V.DELTA.2 Receptor Expression in Peripheral Blood Mononuclear Cells of Active Tuberculosis Patients Before and After Treatment.

Kurume Medical Journal
Medicine
2000English

Non-V Delta 2 Gamma Delta T Lymphocytes as Effectors of Cancer Immunotherapy

OncoImmunology
OncologyAllergyImmunology
2014English

Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN- -Secreting Cells as They Differentiate Into Effector T Cells in Vivo

Cancer Research
Cancer ResearchOncology
2012English

Risedronate Therapy for the Prevention of Steroid-Induced Osteoporosis in Patients With Minimal-Change Nephrotic Syndrome

Internal Medicine
Internal MedicineMedicine
2010English

Crystal Structures of the Osteoporosis Drug Risedronate

Acta Crystallographica Section A Foundations of Crystallography
2007English

Monthly Risedronate for the Treatment of Postmenopausal Osteoporosis

Pharmaceutica Analytica Acta
2014English

Transparency : Can Central Banks Commit to Truthful Communication?

2012English

Cost-Effectiveness of Teriparatide Compared With Alendronate and Risedronate for the Treatment of Postmenopausal Osteoporosis Patients in Iran

Medical Journal of the Islamic Republic of Iran
Medicine
2017English

Orally Administrated Dipeptide Ser-Tyr Efficiently Stimulates Noradrenergic Turnover in the Mouse Brain

Bioscience, Biotechnology and Biochemistry
Organic ChemistryApplied MicrobiologyMolecular BiologyBiochemistryAnalytical ChemistryMedicineBiotechnology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy